Messenger Ribonucleic Acid (mRNA) Combination Vaccine Market Report 2026

Messenger Ribonucleic Acid (mRNA) Combination Vaccine Market Overview

• Messenger Ribonucleic Acid (mRNA) Combination Vaccine market size has reached to $13.18 billion in 2025 • Expected to grow to $31.57 billion in 2030 at a compound annual growth rate (CAGR) of 19.1% • Growth Driver: Rising Burden Of Respiratory Diseases Fueling The Market Growth Through Increasing Demand For Combined Respiratory Protection • Market Trend: Next-Generation Dual-Target mRNA Vaccines Improve Immunization Efficiency • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Messenger Ribonucleic Acid (mRNA) Combination Vaccine Market?

A messenger ribonucleic acid (mRNA) combination vaccine is a vaccine that uses messenger RNA (mRNA) technology to protect against multiple diseases or virus strains in a single shot. It works by delivering genetic instructions that help the body produce specific proteins and trigger an immune response. mRNA combination vaccines are designed to improve convenience, reduce the number of injections, and provide broader protection. The main combination types of messenger ribonucleic acid (mRNA) combination vaccine include COVID-19 plus influenza, COVID-19 plus respiratory syncytial virus, influenza plus respiratory syncytial virus, and pan-respiratory triple combo. COVID-19 plus influenza refers to a combined mRNA vaccine formulation designed to provide protection against both SARS-CoV-2 and seasonal influenza in a single dose. These vaccines are developed for patient populations including adults eighteen to sixty-four, elderly sixty-five and above, immunocompromised patients, and pediatric patients and are distributed through hospital, retail pharmacy, public health programs, and travel clinics.

What Is The Messenger Ribonucleic Acid (mRNA) Combination Vaccine Market Growth Forecast?

The messenger ribonucleic acid (mRNA) combination vaccine market size is expected to see rapid growth in the next few years. It will grow to $31.57 billion in 2030 at a compound annual growth rate (CAGR) of 19.1%. The growth in the forecast period can be attributed to advancement in multi-pathogen vaccine platforms, increasing demand for convenient vaccination schedules, growth in personalized vaccine development, rising focus on elderly and immunocompromised populations, expansion of global vaccine accessibility programs. Major trends in the forecast period include development of pan-respiratory vaccine platforms, increasing focus on single-dose combination immunization, rising demand for age-specific vaccine formulations, expansion of next-generation multi-pathogen vaccine development, increasing investments in broad-spectrum respiratory disease prevention.

Global Messenger Ribonucleic Acid (mRNA) Combination Vaccine Market Segmentation

1) By Combination Type: COVID-19 Plus Influenza; COVID-19 Plus Respiratory Syncytial Virus; Influenza Plus Respiratory Syncytial Virus; Pan-Respiratory Triple Combo 2) By Patient Population: Adults Eighteen To Sixty-Four; Elderly Sixty-Five And Above; Immunocompromised Patients; Pediatric Patients 3) By Distribution Channel: Hospital; Retail Pharmacy; Public Health Programs; Travel Clinics Subsegments: 1) By COVID-19 Plus Influenza: Seasonal Combination Vaccines; Booster Combination Vaccines; Quadrivalent Influenza Combination Vaccines; High Dose Combination Vaccines; Adjuvanted Combination Vaccines 2) By COVID-19 Plus Respiratory Syncytial Virus: Adult Combination Vaccines; Elderly Combination Vaccines; Pediatric Combination Vaccines; Single Dose Combination Vaccines; Multi Strain Combination Vaccines 3) By Influenza Plus Respiratory Syncytial Virus: Seasonal Respiratory Vaccines; High Risk Population Vaccines; Long Acting Combination Vaccines; Enhanced Immunogenicity Vaccines; Recombinant Combination Vaccines 4) By Pan-Respiratory Combination Vaccines: Multi Pathogen Combination Vaccines; Universal Respiratory Vaccines; Broad Spectrum Respiratory Vaccines; Next Generation Respiratory Vaccines; Personalized Respiratory Vaccines

What Is The Driver Of The Messenger Ribonucleic Acid (mRNA) Combination Vaccine Market?

The rising burden of respiratory diseases is expected to propel growth of the messenger ribonucleic acid (mRNA) combination vaccine market going forward. Respiratory diseases are infectious conditions that affect the lungs and respiratory tract, including influenza, COVID-19, and respiratory syncytial virus (RSV), and they create significant healthcare and economic burdens worldwide. The burden of respiratory diseases is increasing due to the continued spread of seasonal and viral respiratory infections across aging and high-risk populations. The messenger ribonucleic acid (mRNA) combination vaccine helps in respiratory disease prevention by enabling protection against multiple respiratory viruses through a single immunization, improving vaccination efficiency and public health coverage. For instance, in November 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, the 2023–2024 influenza season caused approximately 40 million illnesses, 470,000 hospitalizations, and 28,000 deaths in the United States, compared to the previous 2022–2023 season, reflecting increases of around 29.0% in illnesses, 30.6% in hospitalizations, and 33.3% in deaths. Therefore, the rising burden of respiratory diseases is driving the growth of the messenger ribonucleic acid (mRNA) combination vaccine industry.

Key Players In The Global Messenger Ribonucleic Acid (mRNA) Combination Vaccine Market

Major companies operating in the messenger ribonucleic acid (mrna) combination vaccine market are Moderna Inc.; Pfizer Inc.; BioNTech SE; Sanofi S.A.; GSK; CSL Limited; Arcturus Therapeutics Holdings Inc.; CureVac; Merck & Co.; Daiichi Sankyo; CSPC Pharmaceutical Group Limited; Walvax Biotechnology Co. Ltd.; Translate Bio (Sanofi); Gritstone bio Inc.; HDT Bio Corp.; Gennova Biopharmaceuticals Limited; Ethris GmbH; eTheRNA immunotherapies NV; Providence Therapeutics Holdings Inc.; Abogen Biosciences Co. Ltd.; Immorna Biotherapeutics Inc.; Replicate Bioscience Inc.; PopVax Inc.; GeneOne Life Science Inc.

Global Messenger Ribonucleic Acid (mRNA) Combination Vaccine Market Trends and Insights

Major companies operating in the messenger ribonucleic acid (mRNA) combination vaccine market are focusing on developing advanced multivalent vaccine solutions, such as dual-target mRNA vaccines to enhance immunization efficiency, improve protection against multiple respiratory diseases, and simplify annual vaccination programs. Dual-target mRNA vaccines refer to vaccines that use messenger RNA technology to simultaneously target and generate immune protection against two distinct diseases, pathogens, or antigens within a single formulation. For instance, in April 2026, Moderna, a US-based biotechnology company specializing in messenger RNA (mRNA) therapeutics and vaccines, received European Commission marketing authorization for mCOMBRIAX, the world’s first approved mRNA combination vaccine targeting both seasonal influenza and COVID-19 in a single shot. Authorized for adults aged 50 years and older, the vaccine is designed to simplify annual respiratory immunization programs, improve vaccination coverage, and provide enhanced protection against multiple circulating respiratory viruses through Moderna’s mRNA platform.

What Are Latest Mergers And Acquisitions In The Messenger Ribonucleic Acid (mRNA) Combination Vaccine Market?

In December 2025, BioNTech, a Germany-based biotechnology company, acquired CureVac N.V. for $1.25 billion. Through this acquisition, BioNTech aimed to strengthen its mRNA platform technologies and expand its capabilities in developing combination vaccines for COVID-19 and influenza. CureVac N.V. is a Germany-based biotechnology company specializing in mRNA therapeutics and combination respiratory vaccine development.

Regional Outlook

North America was the largest region in the messenger ribonucleic acid (mRNA) combination vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Messenger Ribonucleic Acid (mRNA) Combination Vaccine Market?

The messenger ribonucleic acid (mRNA) combination vaccine market consists of sales of multivalent respiratory vaccines, personalized cancer mRNA vaccines, lipid nanoparticle (LNP) vaccine formulations, and related booster vaccine products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Messenger Ribonucleic Acid (mRNA) Combination Vaccine Market Report 2026?

The messenger ribonucleic acid (mrna) combination vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the messenger ribonucleic acid (mrna) combination vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.